Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Says Seniors Are Missing Out On Medicare Savings

The US Association Has Urged Policymakers To Modernize Medicare Part D

Executive Summary

The AAM’s latest study reveals that the Medicare Part D program continues to underperform compared to commercial plans in providing patients with access to generic medicines. The industry association has also urged policymakers to modernize Medicare Part D.

You may also be interested in...



‘Middlemen’ Markups Are Penalizing Patients, Says AAM

The Association for Accessible Medicines has launched its Markup Madness campaign, which seeks to draw attention to the disparity in cost between generic drugs upon entry to the supply chain and when purchased in pharmacies.

Medicare Is Overpaying For Generics, Says JAMA Study

A study published in the Journal of the American Medical Association has found that while Medicare coverage of generic drugs likely improves patient adherence and reduces other health care utilization, inefficiencies stemming from its “complex and opaque system of intermediaries” mean that it has overpaid on most prescription generics compared to retailer Costco. 

AAM Slams Medicare Delays For First Generics

The AAM has cited multiple reasons for the failure of Medicare Part D to get new generics to its patients, forcing up their costs. The association has offered a list of suggestions to “ensure that first generics are covered at launch, with lower cost-sharing.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel